EU legislation on medicines for children and rare diseases - consultation opens


  • Mary Corcoran
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Commission is inviting health professionals to help shape the European Union (EU) policy on medicines for children and rare diseases by taking part in a new public consultation

joint evaluation on the legislation on medicines for children and rare diseases is currently underway, which aims to assess the efficiency and effectiveness of current regulations, particularly in light of the latest pharmaceutical developments. It will also look at the impact of incentives introduced for research, development and marketing for these specific medicines. Global developments in the area of orphan medicinal products will also be considered given that both the development for medicines in children and for rare diseases are often global.

The consultation is aimed at both healthcare professionals treating patients with rare diseases and individual citizens, with the European Commission asking those taking part to share their experiences with and perspectives on access to orphan medicines in general and on the role EU Orphan Regulation plays in the development of orphan medicines.

Interested participants can contribute to the consultation by completing an online questionnaire. The closing date for submissions is 4 January 2019.